National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't Prospective Studies Clinical Trial Randomized Controlled Trial Double-Blind Method Multicenter Study Survival Analysis risk fibrin fibrinogen degradation products / analysis interleukin-6 / blood pmid:11236773 doi:10.1056/nejm200103083441001 g r bernard j l vincent recombinant human protein c worldwide evaluation in severe sepsis (prowess) study group anti-inflammatory agents non-steroidal / adverse effects non-steroidal / pharmacology non-steroidal / therapeutic use* fibrinolytic agents / adverse effects fibrinolytic agents / pharmacology fibrinolytic agents / therapeutic use* hemorrhage / chemically induced infections / physiopathology protein c / adverse effects protein c / pharmacology protein c / therapeutic use* recombinant proteins / adverse effects recombinant proteins / pharmacology recombinant proteins / therapeutic use* systemic inflammatory response syndrome / blood systemic inflammatory response syndrome / drug therapy* systemic inflammatory response syndrome / mortality